nach oben

Digestive Diseases and Sciences

Erschienen in:

01.01.2011 | Original Article

Intima-Media Thickness of the Common Carotid Artery Is Not Significantly Higher in Crohn’s Disease Patients Compared to Healthy Population

verfasst von: Efrat Broide, Andrei Schopan, Michael Zaretsky, Nimrod Alain Kimchi, Michael Shapiro, Eitan Scapa

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with Crohn’s disease might have accelerated atherosclerosis due to: chronic systemic inflammation, metabolic changes or prolonged steroid treatment.

Aims

The aim of this study was to assess the risk of sub-clinical atherosclerosis in Crohn’s disease, by measuring the intima-media thickness and peak systolic velocity of the common carotid artery.

Methods

Fifty Crohn’s disease patients aged between 20 and 45 years were compared to 25 controls. Patients with a family history of cardiovascular diseases or a known risk for atherosclerosis were excluded. All participants underwent nutritional assessment. Carotid artery ultrasonography was performed and intima-media thickness and peak systolic velocity were measured, proximal to the common carotid bifurcation. Clinical data and laboratory parameters (hemoglobin, highly sensitive C-reactive protein, and plasma homocysteine) were determined.

Results

No significant differences between the groups were found for intima-media thickness or peak systolic velocity. Multiple regression analysis revealed a positive correlation of intima-media thickness with older age. Peak systolic velocity was negatively associated with age.

Conclusions

Crohn’s disease patients do not have an increased risk for developing early atherosclerosis.

Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664–1672.CrossRefPubMed

Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108:1772–1778.CrossRefPubMed

Ripollés Piquer B, Nazih H, Bourreille A, et al. Altered lipid apolipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–988.CrossRefPubMed

Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1897.CrossRefPubMed

Tilg H. Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization, 1–3 March 2007, Innsbruck, Austria. Expert Opin Ther Targets. 2007;11:853–856.CrossRefPubMed

Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physio. 1997;273:G769–G775.

Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease. Contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005;11:304–313.CrossRefPubMed

Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation. 2001;8:283–301.PubMed

Talbot RW, Heppell J, Dozois PR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140–145.PubMed

10.

Webbwerly MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.CrossRef

11.

Van-Doornum S, McColl G, Wicks IP. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862–873.CrossRefPubMed

12.

Sattar N, McCarey DW, Capell H, McInness IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2963.CrossRefPubMed

13.

Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–2406.CrossRefPubMed

14.

Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2006;10:7–11.PubMed

15.

Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.CrossRefPubMed

16.

Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gasteroenterol. 2007;102:662–667.CrossRef

17.

Papa A, Santoliquido A, Danese S, et al. Increased carotid intima–media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.CrossRefPubMed

18.

Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.CrossRefPubMed

19.

Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed

20.

Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol. 1997;146:483–494.PubMed

21.

Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The muscattine study. Circulation. 2001;104:2815–2819.CrossRefPubMed

22.

Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1489–1497.CrossRefPubMed

23.

Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis. 2004;176:1–19.CrossRefPubMed

24.

Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology. 2003;42:292–297.CrossRefPubMed

25.

Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46:1714–1719.CrossRefPubMed

26.

Paoletti R, Gotto A, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(Suppl III):III-20–III-26.CrossRef

27.

Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid and fibrinogen with prevalent coronary heart disease–baseline findings of the PAIS project. Atherosclerosis. 2001;156:451–456.CrossRefPubMed

28.

Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;6:619–623.CrossRef

29.

Feigin VL, Anderseon CS, Mhurchu CN. Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. Cerebrovasc Dis. 2002;113:219–224.CrossRef

30.

Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825–2830.CrossRefPubMed

31.

Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis. 1992;3:773–778.CrossRefPubMed

32.

Souto JC, Martínez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995;40:1883–1889.CrossRefPubMed

33.

Younes-Mhenni S, Derex L, Berruyer M, et al. Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci. 2004;221:113–115.CrossRefPubMed

34.

Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100:886–895.CrossRefPubMed

35.

Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933–938.CrossRefPubMed

36.

Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165–176.PubMed

37.

The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288:2015–2023.CrossRef

38.

Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenetrol Hepatol. 2008;6:41–45.CrossRef

39.

Mutlu B, Ermeydan CM, Enc F, et al. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol. 2002;83:183–185.CrossRefPubMed

40.

Sandrock M, Hansel J, Schulze J, et al. Sequentially based analysis versus image based analysis of intima media thickness in common carotid arteries studies—do major IMT studies underestimate the true relations for cardio- and cerebrovascular risk? Cardiovasc Ultrasound. 2008;6:32.CrossRefPubMed

41.

Hrabovsky V, Zadák Z, Bláha V, Hypsler R, Karlík T. Changes in lipid metabolism in patients in the active phase of Crohn’s disease. Vnitr Lek. 2007;3:1035–1039.

Titel: Intima-Media Thickness of the Common Carotid Artery Is Not Significantly Higher in Crohn’s Disease Patients Compared to Healthy Population
verfasst von: Efrat Broide
Andrei Schopan
Michael Zaretsky
Nimrod Alain Kimchi
Michael Shapiro
Eitan Scapa
Publikationsdatum: 01.01.2011
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-010-1235-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Characterization of Expression in Mice of a Transgene Containing 3.3 kb of the Human Lactase-Phlorizin Hydrolase (LPH) 5′ Flanking Sequence

Long-Term Effect of Interferon Therapy in Patients with HBeAg Positive Chronic Hepatitis B Infection

Capsule Endoscopy in the Diagnosis of Suspected Small Bowel Involvement with Crohn’s Disease

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects